NASDAQ:VRNM - Verenium Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$3.99
Today's RangeN/A
52-Week Range$2.00 - $4.00
Average Volume240,414 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.

Receive VRNM News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:VRNM



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Verenium (NASDAQ:VRNM) Frequently Asked Questions

What is Verenium's stock symbol?

Verenium trades on the NASDAQ under the ticker symbol "VRNM."

Has Verenium been receiving favorable news coverage?

News headlines about VRNM stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verenium earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the next several days.

Who are Verenium's key executives?

Verenium's management team includes the folowing people:
  • James H. Cavanaugh Ph.D., Independent Chairman of the Board (Age 77)
  • James E. Levine, President, Chief Executive Officer, Director (Age 43)
  • Jeffrey G. Black, Chief Financial Officer, Senior Vice President (Age 48)
  • Janet S. Roemer, Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit (Age 57)
  • Alexander A. Fitzpatrick, Senior Vice President, General Counsel, Secretary (Age 47)
  • John F. Dee, Independent Director (Age 56)
  • Peter R Johnson, Independent Director (Age 61)
  • Fernand J. Kaufmann, Independent Director (Age 70)
  • Holger A. Liepmann, Independent Director (Age 63)
  • Joshua Ruch, Independent Director

How do I buy shares of Verenium?

Shares of VRNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Verenium?

Verenium's mailing address is 3550 John Hopkins Ct, SAN DIEGO, CA 92121-1121, United States. The biotechnology company can be reached via phone at +1-858-4318500.

MarketBeat Community Rating for Verenium (NASDAQ VRNM)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Verenium and other stocks. Vote "Outperform" if you believe VRNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel